CAMP4 Therapeutics

Recent Finacing

Series B

Recent Raise

$100M

CAMP4 develops an RNA Actuating Platform mapping cis-regulatory RNAs using NGS/AI to design antisense oligonucleotide RNA actuators that tunably upregulate gene expression in CNS, liver, and other tissues.

Founded 2016

Massachusetts, United States

11-50

Publicly Traded

camp4tx.com

Highlights

Focus Areas

Biopharma

Biotechnology

Therapeutics

Recent Investors

Financials

$175M

Total Raised

3

Funding rounds

7

Investors

Team

Upgrade to view the team

See the team members at CAMP4 Therapeutics.